Inve India ▾

MOLBIO share price & results

MOLBIO· Healthcare

Results to
Jun 2026
Latest analysed call
Q1 FY27
Ownership as of
Sept 2026

Company research is public. Sign in to keep your own companies, notes and cases.

Reported

The figures, each with its period

Each figure keeps its basis and period; nothing is filled in.

MetricValueChangeBasisPeriodNote
Revenue399 ₹ crore+320.0% YoYQuarterly, as filedQuarter to Jun 2026Revenue from operations as filed.
Operating margin23.0 %+33.0 pts YoYOperating profit / revenueQuarter to Jun 2026For the quarter; a change is in percentage points.
Net profit57.0 ₹ crore—Quarterly, as filedQuarter to Jun 2026Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown.
Return on equityUnavailable−1.5 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.
Free cash flow margin0.00 %−22.7 ptsFY Mar 2026 vs FY Mar 2025Fiscal yearFY ending Mar 2026(Operating cash flow − fixed-asset purchases + disposals) ÷ revenue.
Revenue growth (YoY)Unavailable+19.9 ptsFY Mar 2026 vs FY Mar 2025Trailing twelve monthsTTM · period unavailableNot in the analysed materials. No older figure is substituted.

Source: Inve data from filed results; ratios from the Screener-verified panel · to Jun 2026

Guidance

What management said, and what became of it

7 targets tracked, none judged yet · 7 open · verdicts reflect calls analysed to Q1 FY27.

MOLBIO management guidance track record on Inve: 7 targets tracked across analysed earnings calls (0 achieved, 0 missed, 7 open).

TargetOriginal wordingSaidLatest callVerdict
Top line growthroughly about 25%
Call transcript, Q1 FY27 · 8 Sept 2026		Q1 FY27Q1 FY27:Management guided for ~25% top line growth for FY27.
Call transcript, Q1 FY27 · 8 Sept 2026		New

Source: Inve Guidance Tracker for MOLBIO · to Q1 FY27

A verdict describes what became of management’s own words in later analysed calls. “Delayed” is a change of date, “went quiet” a target the calls stopped mentioning. None of it is a judgement on the investment. The methodology sets out how verdicts are recorded.

7 of MOLBIO's 7 targets are still open. See which are on track and which have gone quiet. The 1 above are the free sample; 6 more targets are in the full ledger.

Free account: 5 full ledgers a month and one Inve Case. Pro opens 100 a month, ₹499.
See the full record

Price

₹1,265.8 −0.60% · −₹7.7

Last close 27 Oct 2026 · NSE · INR · Source: Inve

Performance +21.5% YTD

₹1.0k₹1.2k₹1.4k₹1.6kAugSeptOctQ1 FY27 — 8 Sept 2026

YTD: ₹1,041.7 on 17 Aug 2026 → ₹1,265.8. High ₹1,574.4 (16 Oct 2026), low ₹1,036.65 (19 Aug 2026).

Previous close
₹1,273.5
Market cap
₹14.7k Cr
52-week range
₹1,036.65 – ₹1,574.4
Price to earnings (FY ending Mar 2026)
87.88×
Return on equity (FY ending Mar 2026)
15.63%

Overview

Symbol
NSE:MOLBIO
Exchange
NSE
Currency
INR

How the price took the results

close before → close after

Q1 FY27
−0.9%
8 Sept

The move from the last close before each results date to the first close after it — the market's first read on the quarter, not the quarter itself.

Your own record

Start an Inve Case for MOLBIO

Free account: one company. Everything above stays public.

Write why you follow MOLBIO and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.

What an account adds

Keep reading

Other Healthcare companies

All Healthcare companies → · Healthcare earnings growth →

Learn to analyse MOLBIO

Guides on how to read this kind of business and the numbers that matter.